Compass Therapeutics Statistics
Share Statistics
Compass Therapeutics has 138.28M
shares outstanding. The number of shares has increased by 0.5%
in one year.
| Shares Outstanding | 138.28M |
| Shares Change (YoY) | 0.5% |
| Shares Change (QoQ) | 0.5% |
| Owned by Institutions (%) | 73.67% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1 |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 7.63M, so 5.54% of the outstanding
shares have been sold short.
| Short Interest | 7.63M |
| Short % of Shares Out | 5.54% |
| Short % of Float | 7.84% |
| Short Ratio (days to cover) | 10.7 |
Valuation Ratios
The PE ratio is -4.66 and the forward
PE ratio is -4.26.
Compass Therapeutics's PEG ratio is
0.82.
| PE Ratio | -4.66 |
| Forward PE | -4.26 |
| PS Ratio | 0 |
| Forward PS | 0.7 |
| PB Ratio | 1.33 |
| P/FCF Ratio | -4.88 |
| PEG Ratio | 0.82 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Compass Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.73,
with a Debt / Equity ratio of 0.01.
| Current Ratio | 19.73 |
| Quick Ratio | 19.73 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.04 |
| Debt / FCF | -0.04 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,214,114.29 |
| Employee Count | 35 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 28.57% in the
last 52 weeks. The beta is 1.19, so Compass Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.19 |
| 52-Week Price Change | 28.57% |
| 50-Day Moving Average | 2.01 |
| 200-Day Moving Average | 1.92 |
| Relative Strength Index (RSI) | 54.31 |
| Average Volume (20 Days) | 1,498,505 |
Income Statement
| Revenue | n/a |
| Gross Profit | -1.89M |
| Operating Income | -50.36M |
| Net Income | -42.49M |
| EBITDA | -48.47M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.33 |
Full Income StatementBalance Sheet
The company has 24.23M in cash and 1.73M in
debt, giving a net cash position of 22.5M.
| Cash & Cash Equivalents | 24.23M |
| Total Debt | 1.73M |
| Net Cash | 22.5M |
| Retained Earnings | -315.31M |
| Total Assets | 149.15M |
| Working Capital | 136.71M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -40.62M
and capital expenditures -30K, giving a free cash flow of -40.65M.
| Operating Cash Flow | -40.62M |
| Capital Expenditures | -30K |
| Free Cash Flow | -40.65M |
| FCF Per Share | -0.32 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
